ZURA (Zura Bio) EPS (Basic) : $-0.70 (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio EPS (Basic)?

Zura Bio's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.70.

Zura Bio's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.70.

Zura Bio's EPS without NRI for the three months ended in Mar. 2025 was $-0.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -0.65.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Zura Bio EPS (Basic) Historical Data

The historical data trend for Zura Bio's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio EPS (Basic) Chart

Zura Bio Annual Data

Trend

Mar22

Dec23

Dec24

EPS (Basic)

-2.09

-0.60

Zura Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial									-0.02	-0.17	-0.26	-0.08	-0.19

Zura Bio EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zura Bio's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-52.403	-	0)	/	75.071
	=	-0.70

Zura Bio's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-17.442	-	0)	/	92.964
	=	-0.19

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70

Zura Bio (NAS:ZURA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zura Bio EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Zura Bio's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.zurabio.com

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Executives

Parvinder Thiara	director, 10 percent owner	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout	director	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi	director	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell	officer: SVP, Translational Medicine	4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd.	10 percent owner	8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc	10 percent owner	6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry	officer: EVP and CHRO	3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale	officer: EVP and CTO	2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis	officer: Secretary and General Counsel	C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni	director	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192